Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co.,...

SBI Research Outlines LTCG Tax Headroom as Air Suvidha Rule Mandated for All Arrivals
Sony kicks off 2026 PlayStation Store Black Friday sale early with up to 75% off games
Democrats Sweep US Midterm Elections, Winning Senate and House as Trump Faces Lame-Duck Presidency
Union Cabinet Approves Two-Year Extension for Agniveer Service Tenure
Kerala Lottery DhanaLekshmi DL-76 results declared for November 4 draw 


















